Management of Hashimoto's Thyroiditis with Levothyroxine Replacement Therapy

Clinical Presentation and Diagnosis

Hashimoto's thyroiditis requires thyroid hormone replacement therapy with levothyroxine in symptomatic patients with any degree of TSH elevation or in asymptomatic patients with persistently elevated TSH levels above 10 mIU/L, as recommended by the American College of Clinical Oncology 1
Diagnosis typically involves measuring TSH and free T4 levels, with additional testing for thyroid peroxidase antibodies (TPOAbs), according to the American College of Clinical Oncology 1

Levothyroxine replacement therapy is the standard treatment for hypothyroidism in Hashimoto's thyroiditis, with dosing recommendations of approximately 1.6 mcg/kg/day based on ideal body weight for patients without risk factors, as suggested by the American College of Clinical Oncology 1
For patients over 70 years and/or frail patients with comorbidities, a lower dose of 25-50 mcg is recommended, with gradual titration, according to the American College of Clinical Oncology 1
Monitor TSH every 6-8 weeks while titrating hormone replacement to achieve TSH within reference range, as recommended by the American College of Clinical Oncology 1
Once adequately treated, repeat testing every 6-12 months or as indicated by symptom changes, according to the American College of Clinical Oncology 1

Beta-blockers (e.g., atenolol or propranolol) are recommended for symptomatic relief, with close monitoring of thyroid function every 2-3 weeks to detect transition to hypothyroidism, as suggested by the American Academy of Clinical Endocrinologists 2
For persistent thyrotoxicosis (>6 weeks), referral to endocrinology for additional workup is recommended, according to the American Academy of Clinical Endocrinologists 2

Development of low TSH on therapy suggests overtreatment or recovery of thyroid function; dose should be reduced or discontinued with close follow-up, as recommended by the American College of Clinical Oncology 1